incubator records first big hit
"Corridor 1" business incubator, co-sponsored by the
U.Va. Patent Foundation and the Darden School, scored its first
success recently when Adenosine Therapeutics LLC signed a licensing
agreement with DuPont Pharmaceuticals Company for development
of two compounds for use in the heart imaging field.
compounds, ATL-146e and ATL-193, were invented by Joel Linden,
a professor of medicine, and Timothy MacDonald, who chairs U.Va.'s
chemistry department. They potentially represent an advancement
in the diagnosis and prognosis of coronary artery disease in up
to 2 million patients annually without the side effects of currently
available drugs, said Robert Capon, co-founder and CEO of Adenosine
has agreed to pay Adenosine Therapeutics an undisclosed licensing
fee, and will fund a three-year research program, clinical trials,
with milestone payments tied to clinical accomplishments and royalties.
Therapeutics retains the rights to the use of the compounds in
other, non-heart-imaging applications.